• # LGM Pharma is a Tetracosactide CAS# 16960-16-0 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, samples, sourcing, purity and more.
  • # Questions? Call our customer API support number 1-(800)-881-8210.
  • # LGM Pharma offers this active ingredient but not the finished dosage forms.
  • Inquire about this product >>

Product Details:

  • Product Name: Tetracosactide
  • CAS #: 16960-16-0
  • Mode of Action:

    Cosyntropin combines with a specific receptor in the adrenal cell plasma membrane and, in patients with normal adrenocortical function, stimulates the initial reaction involved in the synthesis of adrenal steroids (including cortisol, cortisone, weak androgenic substances, and a limited quantity of aldosterone) from cholesterol by increasing the quantity of the substrate within the mitochondria. Cosyntropin does not significantly increase plasma cortisol concentration in patients with primary or secondary adrenocortical insufficiency.

  • Pharmacodynamics:

    Cosyntropin exhibits the full corticosteroidogenic activity of natural ACTH. Various studies have shown that the biologic activity of ACTH resides in the N- terminal portion of the molecule and that the 1-20 amino acid residue is the minimal sequence retaining full activity. Partial or complete loss of activity is noted with progressive shortening of the chain beyond 20 amino acid residue. For example, the decrement from 20 to 19 results in a 70% loss of potency. The pharmacologic profile of Cosyntropin is similar to that of purified natural ACTH. It has been established that 0.25 mg of Cosyntropin will stimulate the adrenal cortex maximally and to the same extent as 25 units of natural ACTH. Cosyntropin has less immunogenic activity than ACTH because the amino acid sequence having most of the antigenic activity of ACTH, i.e., amino acids 25-39, is not present in cosyntropin. The extra-adrenal effects which natural ACTH and Cosyntropin have in common include increased melanotropic activity, increased growth hormone secretion and an adipokinetic effect. These are considered to be without physiological or clinical significance.

  • IUPAC: alpha(sup 1-24)-Corticotropin alpha1-24-Corticotropin Tetracosactide
  • ATC: H01AA02
  • DrugBank: DB01284
  • Formula: C136-H210-N40-O31-S
  • Molecular Mass: 2933.47
  • Synonyms: (1-24)alpha-ACTH, Acth 1-24, Acth(sup 1-24), Acth-Z, Acthalpha(1-24), ACTHalpha1-24, Actholain, Adrenocorticotropic hormone 1-24, alpha 1-24 Corticotropin, alpha(sup 1-24)-Acth, Ba 30920, Ba 36716, beta(1-24)-Tetracosactide, beta(sup 1-24)-Corticotropin, beta(sup 1-24)-Tetracosactide, beta-1,24-Corticotrophin, beta-Corticotrophin-(1-24)-tetracosapeptide, BRN 0940671, Corticotropin-(1-24), Cortrophin S, Cortrosinta, Cortrosyn, Cosyntropin, EINECS 241-031-1, HSDB 3307, L-Seryl-L-tyrosyl-L-seryl-L-methionyl-L-glutamyl-L-histidyl-L-phenylalanyl-L-arginyl-L-tryptophylglycyl-L-lysyl-L-prolyl-L-valylglycyl-L-lysyl-L-lysyl-L-arginyl-L-arginyl-L-prolyl-L-valyl-L-lysyl-L-valyl-L-tyrosyl-L-proline, Nuvacthen depot, Porcine ACTH (1-24), Synacthen, Synacthene-retard, Tetracosactid, Tetracosactida, Tetracosactida [INN-Spanish], Tetracosactide, Tetracosactidum, Tetracosactidum [INN-Latin], Tetracosactrin, Tetracosapeptide, UNII-72YY86EA29
  • AHFS Code: 08:28.0
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Streamlined API supply towards initial research stages as well as larger quantities of cGMP material for clinical trials and product commercialization
  • Premium quality GMP certified and fully accredited API manufacturing plants


  • Technical packages as well as access to filed DMF,
    ASMF or CEP (subject to availability)
  • Regulatory and technical assistance towards any
    submission type based on specific customer requirements

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service